Berkshire and Surrey Pathology Services & OncoDNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK

Dr Cheng Boon, oncologist in the private sector and the NHS as well as acting as OncoDNA UK medial director commented

In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. 

This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”.

Dr Nadine Collins, consultant clinical scientist in molecular diagnostics who is based at Royal Surrey NHS Foundation Trust, which is part of Berkshire and Surrey Pathology Services responded:

We are part of a large Pathology organisation based at an NHS Trust that hosts a tertiary cancer referral centre. As such, the Molecular Diagnostics department is always looking for new ways to support oncologists in both the public and the private sectors to find innovative treatment solutions for the benefit of their patients. Providing access to this type of in-depth biomarker testing is one such way we are able to help“.

*OncoDEEP uniquely combines IHC testing and NGS testing, targeting a large cancer panel of over 600 genes and cancer-specific biomarkers. It reveals patients’ response to targeted therapy, immunotherapy, hormonal therapy, chemotherapy and oncology clinical trials – screening for cancer gene mutations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (Tumour mutational Burden, Homologous Recombination Deficiency and Microsatellite Instability Testing) and protein biomarkers.

ABOUT ONCODNA

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

For further information, connect with us on LinkedIn or Facebook.

CLINICAL ENQUIRES 

Dr Cheng Boon, UK Medical Director, OncoDNA

You may also be interested in these resources

Scientific Application Note

Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis

Abstract Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib–osimertinib treatment in the global, observational GioTag study.  Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and...

Scientific Application Note

LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease

CT023 – Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study AACR Annual Meeting 2020 Online Proceedings and Itinerary Planner Home April 28, 2020 ABSTRACT INTRODUCTION  Minimal residual disease...

Share This